OBJECTIVE: Endothelial progenitor cells (EPCs) can differentiate into endothelial cells (ECs) and participate in postnatal vasculogenesis, but the mechanism of EPC differentiation remains largely unknown. We investigated the role of AMP-activated protein kinase (AMPK) in EPC differentiation and functions. METHODS AND RESULTS: Vascular endothelial growth factor caused the phosphorylation of AMPK, acetyl-coenzymeA (CoA) carboxylase (ACC), and eNOS in human cord blood-derived EPCs. The expression of EC markers, including VE-cadherin and intercellular adhesion molecule1 (ICAM-1), was also increased but blocked by Compound C, an AMPK inhibitor. AICAR, an AMPK agonist, increased the phosphorylation of ACC and eNOS and the expression of EC markers in a time- and dose-dependent manner, which reinforces the positive effect of AMPK on EPC differentiation. The effects of AICAR could be blocked by treatment with L-NAME, an eNOS inhibitor. Functionally, AICAR increased but Compound C decreased the angiogenesis of EPCs in vitro and in vivo. Furthermore, lovastatin promoted the activation of AMPK and eNOS, the expression of EC markers, tube formation, adhesion, and in vivo vasculogenesis of EPCs, which could be blocked by treatment with Compound C. CONCLUSIONS: The activation of eNOS by AMPK during EPC differentiation provides a novel mechanism for the pleiotropic effects of statins in benefiting the cardiovascular system.
OBJECTIVE: Endothelial progenitor cells (EPCs) can differentiate into endothelial cells (ECs) and participate in postnatal vasculogenesis, but the mechanism of EPC differentiation remains largely unknown. We investigated the role of AMP-activated protein kinase (AMPK) in EPC differentiation and functions. METHODS AND RESULTS:Vascular endothelial growth factor caused the phosphorylation of AMPK, acetyl-coenzymeA (CoA) carboxylase (ACC), and eNOS in human cord blood-derived EPCs. The expression of EC markers, including VE-cadherin and intercellular adhesion molecule1 (ICAM-1), was also increased but blocked by Compound C, an AMPK inhibitor. AICAR, an AMPK agonist, increased the phosphorylation of ACC and eNOS and the expression of EC markers in a time- and dose-dependent manner, which reinforces the positive effect of AMPK on EPC differentiation. The effects of AICAR could be blocked by treatment with L-NAME, an eNOS inhibitor. Functionally, AICAR increased but Compound C decreased the angiogenesis of EPCs in vitro and in vivo. Furthermore, lovastatin promoted the activation of AMPK and eNOS, the expression of EC markers, tube formation, adhesion, and in vivo vasculogenesis of EPCs, which could be blocked by treatment with Compound C. CONCLUSIONS: The activation of eNOS by AMPK during EPC differentiation provides a novel mechanism for the pleiotropic effects of statins in benefiting the cardiovascular system.
Authors: A H Yin; S Miraglia; E D Zanjani; G Almeida-Porada; M Ogawa; A G Leary; J Olweus; J Kearney; D W Buck Journal: Blood Date: 1997-12-15 Impact factor: 22.113
Authors: T Asahara; T Takahashi; H Masuda; C Kalka; D Chen; H Iwaguro; Y Inai; M Silver; J M Isner Journal: EMBO J Date: 1999-07-15 Impact factor: 11.598
Authors: Chunsheng Liu; Shaohua Wang; Arjun Deb; Karl A Nath; Zvonimir S Katusic; Joseph P McConnell; Noel M Caplice Journal: Circ Res Date: 2005-06-23 Impact factor: 17.367
Authors: Swenja Kröller-Schön; Thomas Jansen; Felix Hauptmann; Andrea Schüler; Tjebo Heeren; Michael Hausding; Matthias Oelze; Benoit Viollet; John F Keaney; Philip Wenzel; Andreas Daiber; Thomas Münzel; Eberhard Schulz Journal: Arterioscler Thromb Vasc Biol Date: 2012-04-26 Impact factor: 8.311
Authors: Yuh Fen Pung; Wai Johnn Sam; James P Hardwick; Liya Yin; Vahagn Ohanyan; Suzanna Logan; Lola Di Vincenzo; William M Chilian Journal: Am J Physiol Heart Circ Physiol Date: 2013-08-30 Impact factor: 4.733
Authors: Brendan Gongol; Traci Marin; I-Chen Peng; Brian Woo; Marcy Martin; Stephanie King; Wei Sun; David A Johnson; Shu Chien; John Y-J Shyy Journal: Proc Natl Acad Sci U S A Date: 2013-02-04 Impact factor: 11.205